# FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-gemcitabine-intravesical-system-for-non-muscle-invasive-bladder-can-973459ce20b1c7b9
Kind: launch · Impact: medium

## In brief

- On September 9, 2025, the FDA approved the gemcitabine intravesical system, marketed as Inlexzo by Janssen Biotech, Inc.
- The approval covers adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).

## Why it matters

It adds a drug-delivery treatment option, given directly into the bladder, for patients whose NMIBC with CIS no longer responds to BCG therapy.

## Timeline

- 2025-09-09: FDA approves gemcitabine intravesical system (Inlexzo) for BCG-unresponsive NMIBC with CIS

## Coverage

- [FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer](http://www.fda.gov/drugs/cancer-approvals/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer) — What's New: Drugs RSS Feed, 2026-11-07

Tags: bladder cancer, fda approval, drug approval, oncology, intravesical therapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science